Company intelligence / Profile preview

Kolibri

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Kolibri is developing next-generation acoustic wave-based bioreactors to revolutionize the scalable production of mammalian cells, with an initial focus on AAV viral vector manufacturing for gene therapies. Their patented technology increases yield up to 10x while reducing costs by as much as 95%, addressing major bottlenecks in advanced therapy manufacturing. The company has raised over $3 million in funding and is advancing toward commercial deployment with industry partners.

Modalities: Gene therapy (AAV vectors)Cell therapyViral vector manufacturing technology
Industry: Non-Drug Biotech

Partnerships

Works with manufacturers of gene/cell therapies using AAV vectors

Beyond the preview

Go deeper on Kolibri.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kolibri.

Explore the full profile